Compare Cassava Sciences Inc (FLNA) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Wayfair Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Wayfair Inc trades at $91.03 (market cap $12.10B). The key difference: Wayfair Inc is far larger — about 227.7× Cassava Sciences Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | W | |
|---|---|---|
Market Cap | $53.14M | $12.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $119.05 |
52-Week Low | $1.09 | $55.38 |
Enterprise Value | -$33.43M | $14.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Wayfair (W) trades at $93.74, up 5.63% today, with bullish technical signals from moving averages and a consensus analyst price target of $93.58. The company reported revenue of $12.46B in 2025 but a net loss of $313M, though recent quarters show earnings beats. Positive cash flow from operations of $534M supports liquidity, while expansion into brick-and-mortar stores and AI integration highlight strategic growth initiatives.
The outlook is cautiously optimistic with strong analyst buy ratings (51.78%) and momentum from recent sales events, but risks include persistent net losses, high debt-to-asset ratio of 95.11%, and competitive e-commerce pressures. Upside potential exists if profitability improves, but investors should monitor execution on physical store expansion and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
